Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.

Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7.

PMID:
20618329
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.

Blood. 1999 Apr 1;93(7):2411-9.

PMID:
10090953
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

PMID:
17910631
[PubMed - indexed for MEDLINE]
4.

Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.

Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.

J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.

PMID:
21150718
[PubMed - indexed for MEDLINE]
5.

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q.

Clin Exp Immunol. 2012 Nov;170(2):167-77. doi: 10.1111/j.1365-2249.2012.04642.x.

PMID:
23039887
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.

Haematologica. 2003 Oct;88(10):1139-49.

PMID:
14555310
[PubMed - indexed for MEDLINE]
Free Article
7.

Optimizing dendritic cell-based immunotherapy in multiple myeloma.

Yi Q, Desikan R, Barlogie B, Munshi N.

Br J Haematol. 2002 May;117(2):297-305.

PMID:
11972511
[PubMed - indexed for MEDLINE]
8.

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.

Lim SH, Bailey-Wood R.

Int J Cancer. 1999 Oct 8;83(2):215-22.

PMID:
10471530
[PubMed - indexed for MEDLINE]
9.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.

Blood. 2002 Mar 1;99(5):1517-26.

PMID:
11861263
[PubMed - indexed for MEDLINE]
Free Article
10.

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.

Blood. 1999 Jul 15;94(2):673-83.

PMID:
10397734
[PubMed - indexed for MEDLINE]
Free Article
11.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.

PMID:
16321824
[PubMed - indexed for MEDLINE]
12.

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.

Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.

Biol Blood Marrow Transplant. 2000;6(6):621-7.

PMID:
11128812
[PubMed - indexed for MEDLINE]
13.

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.

Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H.

Br J Haematol. 2000 Mar;108(4):805-16.

PMID:
10792287
[PubMed - indexed for MEDLINE]
14.

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.

Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H.

Cancer Immunol Immunother. 2013 Aug;62(8):1381-92. doi: 10.1007/s00262-013-1438-2. Epub 2013 Jun 2.

PMID:
23728352
[PubMed - indexed for MEDLINE]
15.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347
[PubMed - indexed for MEDLINE]
16.

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.

Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.

Leukemia. 2004 Jan;18(1):139-45.

PMID:
14574332
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, Pour L, Krivanova A, Sandecka V, Hajek R.

Neoplasma. 2012;59(4):440-9. doi: 10.4149/neo_2012_057.

PMID:
22489700
[PubMed - indexed for MEDLINE]
18.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

PMID:
21771874
[PubMed - indexed for MEDLINE]
Free Article
19.

[Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].

Yin XR, Zhang M, Luo YY, Lin X, He PC, Chen LM, Cai RB, Guo GL.

Ai Zheng. 2005 Jun;24(6):657-62. Chinese.

PMID:
15946473
[PubMed - indexed for MEDLINE]
20.

CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q.

Cancer Immunol Immunother. 2012 Apr;61(4):561-71. doi: 10.1007/s00262-011-1123-2. Epub 2011 Oct 15.

PMID:
22002243
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk